<abstract xmlns="http://www.w3.org/1999/xhtml">Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were administered with doxorubicin (DOX, 1.5 mg kg−1, <italic>i.v.</italic>) to induce heart failure. Specific biomarkers such as BNP, CnT, CRP and ROMs were determined. The cardiac enzymatic anti-oxidant systems were recorded with their electrographic profiles. HR, SBP, DBP and MAP were restored at 5 or 10 mg kg−1 (<italic>p.o</italic>.) of SAC/VAL compared to DOX, followed by reduced levels of creatinine and BNP (<italic>p</italic> &lt; 0.001). Significant improvements (<italic>p</italic> &lt; 0.05) compared to DOX were also noticed in CAT, SOD and LPO with the same doses of SAC/VAL. Specific biomarkers such as BNP, CnT, CRP and ROMs descended significantly (<italic>p</italic> &lt; 0.001) with treatment when compared to their baseline values. Our findings implied that SAC/VAL treatment reduced the inflammation and oxidative stress to improve the cardiac function.</abstract>

Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were administered with doxorubicin (DOX, 1.5 mg kg−1, i.v.) to induce heart failure. Specific biomarkers such as BNP, CnT, CRP and ROMs were determined. The cardiac enzymatic anti-oxidant systems were recorded with their electrographic profiles. HR, SBP, DBP and MAP were restored at 5 or 10 mg kg−1 (p.o.) of SAC/VAL compared to DOX, followed by reduced levels of creatinine and BNP (p < 0.001). Significant improvements (p < 0.05) compared to DOX were also noticed in CAT, SOD and LPO with the same doses of SAC/VAL. Specific biomarkers such as BNP, CnT, CRP and ROMs descended significantly (p < 0.001) with treatment when compared to their baseline values. Our findings implied that SAC/VAL treatment reduced the inflammation and oxidative stress to improve the cardiac function.

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits

Department of Cardiovascular Internal Medicine

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were...

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits

Online veröffentlicht: 31. Dez. 2020

Seitenbereich: 473 - 484

Akzeptiert: 30. Sept. 2020

DOI: https://doi.org/10.2478/acph-2021-0030

Schlüsselwörter
sacubitril, valsartan, doxorubicin-heart failure, inflammation, oxidative stress, natriuretic peptide

© 2021 Chun Yu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits

Online veröffentlicht: 31. Dez. 2020

Seitenbereich: 473 - 484

Akzeptiert: 30. Sept. 2020

DOI: https://doi.org/10.2478/acph-2021-0030

Schlüsselwörtersacubitril, valsartan, doxorubicin-heart failure, inflammation, oxidative stress, natriuretic peptide

© 2021 Chun Yu et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Schlüsselwörter
sacubitril, valsartan, doxorubicin-heart failure, inflammation, oxidative stress, natriuretic peptide